此外, CAR-T技术作为抗肿瘤的新兴手段,T细胞可以选择性地被改造成缺乏CD73/CD39或腺苷受体,从而改善其抗肿瘤效应器功能。总之,由于其在不同类型肿瘤中的上调表达以及对肿瘤免疫的广泛调节作用,靶向CD39目前是免疫肿瘤学中最有前景的方法之一。 参考文献: 1.CD39 Regulation and Functions in T Cells. IntJ Mol ...
此外, CAR-T技术作为抗肿瘤的新兴手段,T细胞可以选择性地被改造成缺乏CD73/CD39或腺苷受体,从而改善其抗肿瘤效应器功能。总之,由于其在不同类型肿瘤中的上调表达以及对肿瘤免疫的广泛调节作用,靶向CD39目前是免疫肿瘤学中最有前景的方法之一。 参考文献: 1.CD39 Regulation and Functions in T Cells. IntJ Mol ...
此外, CAR-T技术作为抗肿瘤的新兴手段,T细胞可以选择性地被改造成缺乏CD73/CD39或腺苷受体,从而改善其抗肿瘤效应器功能。总之,由于其在不同类型肿瘤中的上调表达以及对肿瘤免疫的广泛调节作用,靶向CD39目前是免疫肿瘤学中最有前景的方法之一。 参考文献: 1.CD39 Regulati...
此外, CAR-T技术作为抗肿瘤的新兴手段,T细胞可以选择性地被改造成缺乏CD73/CD39或腺苷受体,从而改善其抗肿瘤效应器功能。总之,由于其在不同类型肿瘤中的上调表达以及对肿瘤免疫的广泛调节作用,靶向腺苷途径目前是免疫肿瘤学中最有前景的方法之一。 参考文献: 1.CD39 Regulation and Functions in T Cells. IntJ Mo...
参考文献: 1.CD39 Regulation and Functions in T Cells. IntJ Mol Sci. 2021 Aug; 22(15): 8068. 2. Current Adenosinergic Therapies: What DoCancer Cells Stand to Gain and Lose? Int J Mol Sci. 2021 Nov; 22(22):12569.
[3] CD39 Regulation and Functions in T Cells (nih.gov), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348030/ [4] Targeting CD39 in cancer | Nature Reviews Immunology, https://www.nature.com/articles/s41577-020-0376-4 PR 稿对接: ...
Skip to main contentSkip to article
Mast cells (MCs) are major contributors to an inflammatory milieu. One of the most potent drivers of inflammation is the cytokine IL-1β, which is produced in the cytoplasm in response to danger signals like LPS. Several controlling mechanisms have been
This CD39high CD8+ T cell population is enriched for cells with the phenotypic and functional profile of terminal exhaustion. These findings provide a new marker of T cell exhaustion, and implicate the purinergic pathway in the regulation of T cell exhaustion. 展开 ...
CD39(+) and CD73(+) T cells displayed effector or memory phenotypes and produced IFN-gamma, thereby linking ectonucleotidase expression to T cell effector functions. An accumulation of conventional and regulatory T cells expressing CD39 and/or CD73 was also detected in the peripheral blood of ...